Results 101 to 110 of about 177,264 (261)

Vascular Response to Sildenafil Citrate in Aging and Age-Related Macular Degeneration. [PDF]

, 2019
Age-related macular degeneration (AMD) - the leading cause of vision loss in the elderly - share many risks factors as atherosclerosis, which exhibits loss of vascular compliance resulting from aging and oxidative stress.
Agrawal, Rupesh, Cheung, Chui Ming Gemmy, Cunefare, David, Farsiu, Sina, Khandelwal, Neha, Migacz, Justin, Tran, Steven, Vuong, Vivian S, Yiu, Glenn   +8 more
core   +2 more sources

Comment on “Positive outcomes of phosphodiesterase type 5 inhibitor on histopathologic and biochemical changes induced by ureteral obstruction” [PDF]

, 2020
Zhipeng Wang, Qiang Lu, Xiangjie Qi
openalex   +1 more source

Phosphodiesterase type 5 inhibitors: Irrational use in Saudi Arabia

Arab Journal of Urology, 2016
To identify the criteria of phosphodiesterase type 5 inhibitor (PDE5i) users and to analyse the knowledge, attitude, and practices of PDE5i use amongst Saudi men.A web-based, cross-sectional survey was conducted in Saudi Arabia between January and April 2015.
Alshahrani, Saad, Ahmed, Abul-Fotouh, Gabr, Ahmed H., Al Ansari, Ahmed, El-feky, Mohamed, Elbadry, Mohamed S.   +5 more
openaire   +2 more sources

Clinically relevant enhancement of human sperm motility using compounds with reported phosphodiesterase inhibitor activity [PDF]

, 2014
STUDY QUESTION: Can we identify compound(s) with reported phosphodiesterase inhibitor (PDEI) activity that could be added to human spermatozoa in vitro to enhance their motility without compromising other sperm functions?
Alasmari, Alasmari, Baker, Barratt, Baxendale, Bjorndahl, Christopher L.R. Barratt, Comhaire, Conti, Cooper, David, Fisch, Ford, Francis, Glenn, Harrison, HFEA, Horvath, Houslay, Huacuja, Hull, Hunnicutt, Irvine, Ivic, Lefièvre, Lefièvre, Lefièvre, Linda Lefièvre, Lorna Frame, Martin, Mortimer, Mrsny, Nassar, Negri, O'Connell, Oladipo A. Madamidola, Paul G. Wyatt, Publicover, Richter, Sarah J. Martins Da Silva, Sean G. Brown, Sousa, Steve Tardif, Stone, Tesarik, Tomlinson, Tomlinson, Torres-Flores, Tournaye, Tournaye, Van der Steeg, Wang, Yang, Yovich, Yovich   +54 more
core   +5 more sources

Avanafil for treatment of erectile dysfunction: review of its potential

Vascular Health and Risk Management, 2012
Ryan M Burke,1 Jeffery D Evans21The University of Louisiana at Monroe College of Pharmacy, Monroe, LA, 2The University of Louisiana at Monroe College of Pharmacy, Shreveport, LA, USAAbstract: Avanafil is a medication that was recently approved by the US ...
Burke RM, Evans JD
doaj  

Phosphodiesterase Type 5 Inhibitors and sudden sensorineural hearing loss

Brazilian Journal of Otorhinolaryngology, 2013
Phosphodiesterase type 5 Inhibitors, such as sildenafil, vardenafil and tadalafil have been increasingly used today and some of the users have developed sudden sensorineural hearing loss.To present two patients with sudden deafness developed after an occasional use of the drug and review studies on the use of phosphodiesterase type 5 inhibitors and ...
Barreto, Monique Antunes de Souza Chelminski, Bahmad, Fayez   +1 more
openaire   +2 more sources

Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink

PLoS Medicine, 2016
Background Laboratory evidence suggests that reduced phosphodiesterase type 5 (PDE5) expression increases the invasiveness of melanoma cells; hence, pharmacological inhibition of PDE5 could affect melanoma risk.
A. Matthews, S. Langan, I. Douglas, L. Smeeth, K. Bhaskaran   +4 more
semanticscholar   +1 more source

Determination of phosphodiesterase type 5 inhibitors in health supplements using liquid chromatography–tandem mass spectrometry (LC–MS/MS)

Tạp chí Kiểm nghiệm và An toàn thực phẩm
Phosphodiesterase type 5 inhibitors (PDE-5i) are the common oral medications prescribed for the treatment of erectile dysfunction (ED). In recent years, health supplements have gained popularity as alternative options to prescription PDE-5i.
Kieu Van Anh, Nguyen Thi Hong Ngoc, Vu Thi Trang, Nguyen Thi Anh Huong, Le Thi Hong Hao   +4 more
doaj   +1 more source

Identification of murine phosphodiesterase 5A isoforms and their functional characterization in HL-1 cardiac cell line [PDF]

, 2017
Phosphodiesterase 5A (PDE5A) specifically degrades the ubiquitous second messenger cGMP and experimental and clinical data highlight its important role in cardiac diseases.
Barbagallo, Federica, Campolo, Federica, Cardarelli, Silvia, Cornacchione, Marisa, DE ARCANGELIS, Valeria, DI GRAZIA, Antonio, Gianfrilli, Daniele, Giorgi, Mauro, Isidori, Andrea, Lenzi, Andrea, Monaco, Lucia, Naro, Fabio, Pellegrini, Manuela, Zevini, Alessandra   +13 more
core   +1 more source

Efficacy of Intracavernosal Injections of 50-Unit Versus 100-Unit Doses of AbobotulinumtoxinA (Masport®) in Vasculogenic Erectile Dysfunction with Phosphodiesterase Type 5 Inhibitors Resistant [PDF]

, 2022
Sajad Moradi, Dinyar Khazaeli, Mohammadreza Dadfar, Nima Bakhtiari   +3 more
openalex   +1 more source